The relationship between isotretinoin treatment for acne and depression is controversial. Quantitative analysis has not yet been conducted.
A cne is a common, chronic skin condition that affects nearly all adolescents. Isotretinoin is the most effective treatment available for recalcitrant nodulocystic acne. 1 The possible induction of depressive symptoms by isotretinoin treatment for acne was first reported in 1983. 2 In 1998, the US Food and Drug Administration issued a warning regarding the possible associations of isotretinoin with depression, psychosis, suicidal ideation, and suicide. However, 2 large populationbased studies in 2000 3 and 2003, 4 as well as several controlled [5] [6] [7] [8] and noncontrolled studies, [9] [10] [11] [12] [13] [14] failed to demonstrate an increased risk for depression or suicide associated with isotretinoin. In 2008, a case cross-over study by Azoulay et al 15 revealed a statistically significant association between isotretinoin and depression. However, a large population-based study 16 found acne alone to be significantly associated with depression and suicidal ideation. Despite the controversy surrounding isotretinoin, the potential increase in the risk for psychological problems associated with severe acne should also be considered. Multiple studies on the relationship between isotretinoin and depression have been conducted, some of which demonstrated that treating acne with isotretinoin improved depressive symptoms. [17] [18] [19] [20] [21] [22] [23] Considering whether sex, isotretinoin dose, treatment time, and the patient baseline psychologic condition affected the results of these studies is crucial. However, with only limited data and small sample sizes, assessing these confounding factors is difficult. Further, 3 systematic reviews by Strahan et al in 2006, 24 Marqueling et al in 2007, 25 and Bremner et al in 2012 26 did not achieve consistent results. Strahan et al 24 and Marqueling et al 25 concluded that the current literature does not support a causative association between isotretinoin and depression. However, Bremner et al 26 concluded that isotretinoin has a causal link with depression. Here we sought to determine the relationship between isotretinoin and depression by providing a thorough, evidence-based metaanalysis of this controversy.
METHODS
This meta-analysis was carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (http://www.prismastatement.org/).
Data source and search strategy
We identified studies indexed in PubMed, MEDLINE, EmBase, and the Cochrane Library databases from inception of isotretinoin treatment to September 30, 2016 , (last literature search day October 4, 2016) . All articles included in the present study involved human clinical studies written in English. The search parameters included the terms ''depression'' combined with ''isotretinoin,'' ''accutane,'' or ''13-cis-retinoic acid.''
Study selection
We primarily focused our literature search on randomized controlled trials (RCTs). However, in the absence of an RCT, we included large-scale population-based studies, non-RCT, and prospective open-label studies with $15 patients with acne who had received isotretinoin therapy. Only studies that provided the prevalence of depression or depression scores were included. Articles from adverse event reporting systems, review articles, case reports, correspondence, and conference report were excluded. Quality assessment was performed using methodological index for nonrandomized studies. 27 The studies with quality scores\12 were also excluded.
Outcomes
The primary outcomes of the present study were the prevalence of depression and change in the depression score following isotretinoin therapy.
Data extraction
Data were independently extracted by 2 authors (Dr Huang and Dr Cheng). Any disagreement was resolved by consensus. Data on the following measures were extracted: study design, inclusion criteria, sample size, treatment regimen, study results, and quality scores (Supplemental Table I ; available at http://www.jaad.org). For populationbased studies, we extracted the outcome (relative risk [RR]) (Supplemental Table II ; available at http:// www.jaad.org). Age, the proportion of male patients, follow-up time, cumulative isotretinoin dose, depression scale, and depression score with standard deviation (SD) before, during, and after treatment were also extracted (Supplemental Tables  III and IV ; available at http://www.jaad.org). We extracted the number of depression cases (Table I) , if provided by the study. The non-RCTs consisted of 2 groups of patients with acne who received isotretinoin or alternative therapy within the same study. Depression was defined by the original study. The cumulative isotretinoin dose was calculated
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J AM ACAD DERMATOL VOLUME 76, NUMBER 6 according to the dose provided in the original study. If the follow-up time was provided in weeks, we calculated a week to be 7 days; if given in months, we calculated a month to be 30 days. The details of the depression scales are shown in Supplemental Table V (available at http://www.jaad.org).
Data analysis
For the controlled trials, we produced a pooled estimate of the mean difference in the depression score change for patients treated with isotretinoin compared with patients who received alternative therapy. For all studies that provided depression scores, we performed a pooled estimate for the change in depression score. If there were $3 studies using the same depression scales, a pooled estimate was also performed. Data were then stratified by follow-up time into 3 groups: 1) 1-2 months; 2) 3-4 months; and 3) past 4 months. Separate meta-analyses were then conducted for each subgroup, as well as a pooled analysis of the prevalence of depression before and after treatment for studies with a clear definition of depression and a depression case number. Continuous data were analyzed using the weighted mean difference when comparing grouped studies using the same scale or standardized mean difference (SMD) when comparing variable and nonstandardized outcome scales reported across studies. Dichotomous analyses were conducted using RR.
For meta-analyses of controlled trials, some studies reported the baseline and final scores for 2 groups. We computed the mean change in the scores from baseline and SD for both the isotretinoin and controlled groups. The data were combined in the same analysis as the studies that reported only the final scores of the 2 groups. This computation requires the preepost correlation value to be input. However, no studies reported the preepost correlation values necessary to conduct an appropriately paired analysis. We used a preepost correlation of 0.5. 33 The same computations were conducted for all meta-analyses in prospective open-label studies with before and after data. Sensitivity analyses were conducted for each case by using preepost correlations of 0.2 and 0.8. If studies lacked necessary data, they were not pooled in the meta-analysis. Similarly, none of the uncontrolled studies that measured dichotomous outcomes before and after treatment reported data in a matched format; therefore, these outcomes were analyzed as unmatched data, shown to be similar and easier to interpret than matched analyses. 34 Homogeneity testing was performed using the I 2 test. A fixed-effects model was used if there was a lack in heterogeneity. When I 2 was[60%, a random-effect model was used. A meta-regression was performed to determine the effect of the cumulative isotretinoin dose, proportion of male patients, high baseline depression scores (studies with baseline scores exceeding the definition of depression, categorical variable), and quality scores on the change of depression 
RESULTS

Search results and trial characteristics
Of the 172 studies screened, the inclusion criteria were met in 31 studies ( Table I .
Of the 31 studies, 1 population-based study found that isotretinoin significantly increased the risk of depression, while 2 open-label studies found increased depression scores following isotretinoin therapy (1 significantly and the other nonsignificantly increased). The other 10 controlled studies and 15 open-label studies found no association between isotretinoin use and the risk for depression. Eleven out of 25 studies (2 controlled 5, 30 and 9 open-label studies 10, 11, 17, [19] [20] [21] [22] [23] 35 ) found a significant improvement in the depression scores or a J AM ACAD DERMATOL VOLUME 76, NUMBER 6 reduced frequency of depression following isotretinoin therapy. The improved depression score was significantly greater than the control group in 1 controlled study and nonsignificant in the other controlled study. The remaining 3 studies only provided the prevalence of depression: 1) 11% mild depression after 1 month of therapy; 2) 4% prevalence of depression from the start to therapy completion; and 3) 0.9% during therapy which resolved with continued treatment (Supplemental Table I ; available at http://www.jaad.org).
Characterization of patients with acne and isotretinoin use
Clinical and outcome data for patients with acne are summarized (Table I, Supplemental Tables II-IV; available at http://www.jaad.org). Excluding the 3 population-based studies, 2932 acne patients were treated with isotretinoin, of which 2611 completed the studies. The isotretinoin regimen was 0.5-1 mg/kg/day in all studies except for 2 with doses of 0.1-0.22 mg/kg/day and 2 mg/kg/day. The cumulative isotretinoin dose ranged from 15-150 mg/ kg. In 4 studies, the mean scores before treatment exceeded the definition of depression using their own scale. The after score increased in 1 study and decreased below the definition point in the 3 others.
Statistical analysis results
The results of the meta-analysis are presented in Table II . For the 6 controlled studies, the depression score changes from baseline were not significantly different (both improved) among the patients treated with isotretinoin or an alternative therapy (SMD À0.334, 95% confidence interval [CI] À0.680 to 0.011) when imputing a 0.5 correlation (Fig 2) .
The prevalence of depression following isotretinoin treatment significantly declined (RR 0.588, 95% CI 0.382-0.904). For the pre-and post-test scores for isotretinoin treatment, the mean depression scores significantly decreased from baseline regardless of the correlation value (SMD À0.335, 95% CI À0.498 to À0.172). The mean depression scores also significantly decreased when assessed by Beck Depression Inventory, Hospital Anxiety Depression ScaleeDepression (HADS-D), followup at 1-2 months, and follow-up past 4 months. The meta-regression revealed that a high proportion of male patients (coefficient 0.0107, 95% CI 0.0015-0.0199; P = .022) and a high quality score (coefficient 0.2403, 95% CI 0.0638-0.4108; P = .0076) were significantly related to less decrement in depression scores. The funnel plot (Fig 3) for change in depression scores in 19 studies showed no publication bias (Egger test, P = .5158). ) without follow-up after completion of isotretinoin treatment.
DISCUSSION
The relationship between isotretinoin treatment for acne and depression remains controversial both clinically and scientifically. Because isotretinoin is a fat-soluble compound, it can easily cross the bloodebrain barrier and interact with brain tissue wherever intracellular retinoid receptors are present. It can affect the dopaminergic 36 and serotonergic systems, 37 hippocampal neurogenesis, 38 and frontal orbital activity. 8 The chronic administration of 1-mg/kg dose of isotretinoin has been shown to increase depression-related behavior in mice and rats in some studies 39, 40 but not in others. 41, 42 This meta-analysis found no association between isotretinoin and depression. Moreover, symptoms of depression improved following isotretinoin treatment, but this effect was not significantly different from alternative therapy. Among studies that could not be used in this meta-analysis, only the populationbased study by Azoulay et al 15 concluded that isotretinoin significantly increased the risk for depression in acne patients. All 3 population-based studies Funnel plot analysis for potential publication bias. The funnel plot for change in depression scores in 19 studies showed no asymmetry, which means no publication bias. Each dot represents a study; the y-axis represents the standard error of the study and the x-axis shows the study result (standardized mean difference of pre-and post-treatment depression scores in each study).
J AM ACAD DERMATOL VOLUME 76, NUMBER 6 underestimated the incidence of depression because diagnostic codes and antidepressant prescriptions were used as inclusion criteria and patients with inadequate data were excluded. Moreover, this underestimation might be particularly problematic for the study by Azoulay et al 15 because the RR estimate was based on a small subset of patients who met strict depression and data availability criteria; therefore, the results might not be applicable to a general population of patients treated with isotretinoin. 43 The systematic review by Bremner et al 26 concluded that isotretinoin had a causal link with depression. Despite their finding that multiple studies demonstrated no association between isotretinoin and depression or an improvement in depressive symptoms following isotretinoin treatment, they concluded that the sample sizes were too small to confirm that most patients receiving isotretinoin did not develop depression. The systematic reviews by Strahan et al, 24 Marqueling et al, 25 and Bremner et al 26 did not include a pooling analysis to derive their conclusion. In our meta-analysis, we pooled the results of 1411 patients who received depression evaluations at baseline and after treatment, which revealed a significant improvement in the depression scores. Bremner et al 26 used the study by Meysken et al 44 to support a dose-response relationship of up to 3 mg/kg/day isotretinoin for advanced cancer patients, 25% of whom exhibited depression. However, high doses that might cause symptoms of depression are not usually prescribed for acne. In our study, the typical dose prescribed for acne (0.5-1 mg/kg) was not found to have a dose-related risk for depression, consistent with the results of the study by Azoulay et al. 15 Bremner et al 26 stated that depression usually develops 1-2 months or sometimes around 2-4 months after treatment and further emphasized that challengeerechallenge cases support a causal link. In our study, the depression scores significantly decreased within the first 1-2 months and after 4 months and tended to decrease (but not significantly) within 3-4 months. Although 4 studies found increased scores at 3-4 months, 2 of them found that scores at 6 months had decreased below baseline despite continued treatment. The other 2 studies involved follow-up for only 3-4 months. Webster et al 31 found that in all patients who reported depression, the condition resolved without discontinuing isotretinoin. Increased depression scores or newly reported depression cases might be explained by the persistence of acne or other side effects of isotretinoin, which might resolve over the course of treatment.
In our study, similar to that in the study by Halvorsen et al, 16 the patients with acne had high baseline depression scores, which exceeded the depression cut-off points of 4 studies. However, meta-regression results revealed that high baseline scores did not affect depression score changes and male patients were as capable of improving depression scores as female patients.
From the view of prevalence of depression, the risk was significantly decreased after treatment. However, some studies described newly developed depression during treatment. In the controlled trial conducted by Suarez et al, 32 new onset of depression was noted in both the isotretinoin and antibiotic groups, implying that depression is associated with acne, independently of isotretinoin. Thus, physicians should consider the possibility of depression among all acne patients regardless of the treatment method. We also agree with Bremner et al 26 that some patients are more susceptible to depression. However, if there is a link between isotretinoin and depression, no predictive tests exist for quantifying the level of risk to patients; perhaps it is an idiosyncratic reaction. 45 Our study has some limitations. The first limitation was that no RCTs were included; however, we included recent studies with the highest level of evidence, all of which demonstrated a weak relationship between isotretinoin and depression. The second limitation was high inter-study variability (eg, different evaluation tools). Therefore, we used the standardized mean difference outcome measure for the meta-analyses of continuous data and performed meta-regression for sensitivity analysis. The quality score affected the change in depression scores: when omitting the studies with the lowest scores, the improvement in depression score remained significant.
In conclusion, this meta-analysis demonstrated that isotretinoin treatment for acne at the typical therapeutic dose is not associated with an increased risk for depression. Moreover, the treatment of acne improved symptoms of depression for most patients. Some patients might be more prone to depression regardless of acne or other conditions. Thus, closely monitoring acne patients for depression is essential to identify patients at a high risk. y Study did not provide enough data, so it was not included in the pooled analysis. z Study lacked the baseline depression score, so it could only be included in pooled meta-analysis of controlled studies.
x In this study, the age and proportion of male patients were collected before treatment but not after treatment.
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Supplemental A patient reporting instrument including 21 groups of 4 statements, in which patients are asked to select the statement that most clearly describes the way they felt in the previous week. The scores are used for measuring symptoms of depression. A widely used scale that was designed specifically to measure some of the most important symptoms of a depressive disorder. It includes 10 items (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimism, and suicidal thoughts), each of which is scored from 0 to 6.
Ratings can be added to form an overall score (range 0-60); no weights are used. Cut-off points include: 0-6 (symptoms absent), 7-19 (mild depression), 30-34 (moderate depression), and 35-60 (severe depression).
MS S9
A 53-item questionnaire producing an 8-factor score. POMS S10 A 65-item questionnaire generating a 6-factor score. Fifteen items contributed to the depression subscale. The intensity and frequency of symptoms is evaluated on a 5-point scale (0-4) with score range 0-60. Zung scale S11 Every scale consisted of 20 items with positive or negative valence that explored the frequency of depression or anxiety signs and symptoms, as follows: from 1 (rarely) to 4 (always).
Each subject was then classified as nondepressed or nonanxious when scoring \50 points or slightly, moderately, or severely depressed or anxious when scoring 50-59, 60-69, and $70 points, respectively.
Scales are enumerated S1-S11. BDI, Beck Depression Inventory; CES-D, Center for Epidemiological Studies Depression; HADS-D, Hospital Anxiety Depression Scale-Depression; HRSD, Hamilton Rating Scale for Depression; HSCL, Hopkins Symptoms Checklist; MADRS, Montgomerye Asberg Depression Rating Scale; MS, National Institute of Mental Health Mood Scale; POMS, Profile of Mood States Scale.
